Ocrelizumab and Other CD20⁺ B-Cell-Depleting Therapies in Multiple Sclerosis

Area of Science:

• Immunology
• Neurology
• Pharmacology

Background:

• Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system.
• Current MS treatments aim to reduce inflammatory relapses and disease progression.
• B cells play a significant role in MS pathogenesis.

Purpose of the Study:

• To review advances in anti-CD20 B-cell-depleting biological therapies for MS.
• To discuss the efficacy and safety of ocrelizumab, rituximab, and ofatumumab in MS treatment.

Main Methods:

• Review of clinical trial data and scientific literature on anti-CD20 therapies in MS.
• Analysis of efficacy in suppressing inflammatory disease activity and disability progression.
• Evaluation of safety profiles, including adverse events and malignancies.

Main Results:

• Anti-CD20 monoclonal antibodies profoundly suppress acute inflammatory disease activity in relapsing-remitting MS.
• Ocrelizumab is the first therapy shown to reduce disability progression in primary progressive MS.
• Common adverse events include infusion reactions and infections; a numerical imbalance in malignancy risk was observed with ocrelizumab.

Conclusions:

• Anti-CD20 B-cell-depleting therapies represent a significant advance in MS treatment.
• Ocrelizumab offers a breakthrough for both relapsing-remitting and primary progressive MS.
• Ongoing monitoring for adverse events, including infections and malignancies, is crucial.